Late-stage study commences for Flexion’s Zilretta in hip osteoarthritis

Jan. 2, 2019 4:54 PMSA Editor Douglas W. House

Enrollment is underway in a Phase 3 clinical trial evaluating Flexion Therapeutics’ (NASDAQ:FLXNZILRETTA (triamcinolone acetonide extended-release injectable suspension) in patients with hip osteoarthritis, a degenerative condition that strikes up to 25% of Americans in their lifetimes.

The primary endpoint is the magnitude of pain relief at week 12 versus placebo as measured by a scale called WOMAC.

The company plans to launch Phase 2 trials in shoulder osteoarthritis and shoulder adhesive capsulitis later this year

Source: Jan. 2, 2019 4:54 PMSA Editor Douglas W. House

anatomy-3003099__340.jpg

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this:
close-alt close collapse comment ellipsis expand gallery heart lock menu next pinned previous reply search share star